Intersection of Uremic Toxins and Biological Sex in Chronic Kidney Disease Progression

Arkansas Children'S Hospital Res Inst, Little Rock AR

Investigators

Linked publications, trials & patents

Abstract

Children with chronic kidney disease (CKD) are at high risk of complications and have a reduced life expectancy compared to healthy peers. The risk of complications and death increases as CKD progresses to higher stages. Childhood CKD is often the result of progressive conditions, such as Alport syndrome, that lead to advanced CKD and kidney failure. Therefore, there is a critical need to identify mechanisms of kidney disease progression in Alport syndrome and related genetic pediatric kidney diseases. As kidney disease progresses, reduced kidney function leads to systemic bioaccumulation of uremic toxins, which are toxic metabolites normally excreted in the urine. Uremic toxins activate the aryl hydrocarbon receptor (Ahr) in the kidneys and other organs, and accumulating evidence suggests that these molecules are not merely byproducts of impaired renal function but contribute to CKD progression. Thus, it is essential to understand the fundamental biological underpinnings of renal clearance of uremic toxins and the effects uremic toxins on the kidneys themselves. In a preliminary study, we found that exposure to the uremic toxin indoxyl sulfate exacerbates CKD progression in Col4a3 knockout mice, a murine model of Alport syndrome, but the effect was sex-specific to males, with female mice being protected. Sex differences in CKD outcomes are well-known, but the mechanism is unclear. There is a significant knowledge gap in relation to sex-specific uremic toxin biology, particular the effects of uremic toxins on the kidneys and sex differences in renal elimination of uremic toxins. In this application we propose to investigate the sex-specific effects of uremic toxin-mediated Ahr activation on CKD progression and the role of sex hormones in regulating the renal elimination of uremic toxins. We will manipulate systemic concentrations of uremic toxins in Col4a3 knockout mice using drugs that promote or inhibit excretion of these molecules. We will delineate the role of Ahr activation in CKD progression in male and female Col4a3 knockout by testing the effect of pharmacologic Ahr inhibition on CKD progression in this model, and by generating congenic Col4a3 knockout mice with high and low ligand-binding affinity Ahr alleles. Finally, we will compare the renal clearance of uremic solutes in male and female Col4a3 knockout mice and will use orchiectomy and ovariectomy to determine the role of sex hormones in modulating renal clearance of uremic toxins.